<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Enzyme replacement therapy with alglucosidase alfa for infantile <z:e sem="disease" ids="C0017921" disease_type="Disease or Syndrome" abbrv="AMD">Pompe disease</z:e> has improved survival creating new management challenges </plain></SENT>
<SENT sid="1" pm="."><plain>We describe an emerging phenotype in a retrospective review of long-term survivors </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Inclusion criteria included ventilator-free status and age ≤6 months at treatment initiation, and survival to age ≥5 years </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical outcome measures included invasive ventilator-free survival and parameters for cardiac, pulmonary, musculoskeletal, gross motor, and ambulatory status; growth; speech, hearing, and swallowing; and gastrointestinal and nutritional status </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Eleven of 17 patients met study criteria </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> were cross-reactive immunologic material-positive, alive, and invasive ventilator-free at most recent assessment, with a median age of 8.0 years (range: 5.4-12.0 years) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had marked improvements in cardiac parameters </plain></SENT>
<SENT sid="7" pm="."><plain>Commonly present were gross motor <z:mp ids='MP_0000746'>weakness</z:mp>, motor speech deficits, sensorineural and/or <z:hpo ids='HP_0000405'>conductive hearing loss</z:hpo>, <z:hpo ids='HP_0000938'>osteopenia</z:hpo>, <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo>, and <z:hpo ids='HP_0002015'>dysphagia</z:hpo> with <z:hpo ids='HP_0002835'>aspiration</z:hpo> risk </plain></SENT>
<SENT sid="8" pm="."><plain>Seven of 11 patients were independently ambulatory and four required the use of assistive ambulatory devices </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> long-term survivors had low or undetectable anti-alglucosidase alfa antibody titers </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Long-term survivors exhibited sustained improvements in cardiac parameters and gross motor function </plain></SENT>
<SENT sid="11" pm="."><plain>Residual <z:hpo ids='HP_0001324'>muscle weakness</z:hpo>, hearing loss, risk for <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, <z:hpo ids='HP_0001614'>hypernasal speech</z:hpo>, <z:hpo ids='HP_0002015'>dysphagia</z:hpo> with risk for <z:hpo ids='HP_0002835'>aspiration</z:hpo>, and <z:hpo ids='HP_0000938'>osteopenia</z:hpo> were commonly observed findings </plain></SENT>
</text></document>